The estimated Net Worth of R Don Elsey is at least $546 mil dollars as of 15 April 2011. Mr Elsey owns over 14,385 units of Lyra Therapeutics stock worth over $9,878 and over the last 18 years he sold LYRA stock worth over $0. In addition, he makes $536,336 as Advisor at Lyra Therapeutics.
Mr has made over 1 trades of the Lyra Therapeutics stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 14,385 units of LYRA stock worth $190,745 on 15 April 2011.
The largest trade he's ever made was exercising 14,385 units of Lyra Therapeutics stock on 15 April 2011 worth over $190,745. On average, Mr trades about 480 units every 0 days since 2006. As of 15 April 2011 he still owns at least 36,584 units of Lyra Therapeutics stock.
You can see the complete history of Mr Elsey stock trades at the bottom of the page.
R. Donald Elsey MBA is the Advisor at Lyra Therapeutics.
As the Advisor of Lyra Therapeutics, the total compensation of Mr MBA at Lyra Therapeutics is $536,336. There are 1 executives at Lyra Therapeutics getting paid more, with Dr. Maria Palasis Ph.D. having the highest compensation of $754,070.
Mr MBA is 67, he's been the Advisor of Lyra Therapeutics since . There are 1 older and 5 younger executives at Lyra Therapeutics. The oldest executive at Lyra Therapeutics, Inc. is Dr. Harlan W. Waksal M.D., 68, who is the Exec. Chairman.
Over the last 4 years, insiders at Lyra Therapeutics have traded over $0 worth of Lyra Therapeutics stock and bought 19,620,470 units worth $85,899,322 . The most active insiders traders include Advisors Llcperceptive Life..., Edward T Anderson, eGp, Llcdamore Richard Anort.... On average, Lyra Therapeutics executives and independent directors trade stock every 76 days with the average trade being worth of $311,619. The most recent stock trade was executed by Harlan Waksal on 10 November 2023, trading 25,000 units of LYRA stock currently worth $74,000.
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Lyra Therapeutics executives and other stock owners filed with the SEC include: